Hudson Capital Management LLC Increases Holdings in Taro Pharmaceutical Industries Ltd. (TARO)

Share on StockTwits

Hudson Capital Management LLC raised its holdings in shares of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) by 12.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,174 shares of the company’s stock after purchasing an additional 1,259 shares during the quarter. Hudson Capital Management LLC’s holdings in Taro Pharmaceutical Industries were worth $946,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Bank of New York Mellon Corp lifted its holdings in shares of Taro Pharmaceutical Industries by 73.1% during the second quarter. Bank of New York Mellon Corp now owns 20,109 shares of the company’s stock worth $2,326,000 after buying an additional 8,492 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Taro Pharmaceutical Industries by 25.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 10,026 shares of the company’s stock worth $1,160,000 after buying an additional 2,054 shares in the last quarter. FMR LLC lifted its holdings in shares of Taro Pharmaceutical Industries by 1.6% during the second quarter. FMR LLC now owns 655,851 shares of the company’s stock worth $75,875,000 after buying an additional 10,562 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Taro Pharmaceutical Industries by 9.8% during the second quarter. Renaissance Technologies LLC now owns 287,000 shares of the company’s stock worth $33,203,000 after buying an additional 25,600 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd lifted its holdings in shares of Taro Pharmaceutical Industries by 31.1% during the second quarter. Dynamic Technology Lab Private Ltd now owns 3,230 shares of the company’s stock worth $374,000 after buying an additional 766 shares in the last quarter. 10.38% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE TARO traded up $0.85 during mid-day trading on Wednesday, reaching $92.12. The company had a trading volume of 6,179 shares, compared to its average volume of 74,373. Taro Pharmaceutical Industries Ltd. has a one year low of $76.93 and a one year high of $121.23. The stock has a market capitalization of $3.62 billion, a P/E ratio of 14.84 and a beta of 0.40.

Taro Pharmaceutical Industries (NYSE:TARO) last issued its quarterly earnings results on Monday, November 5th. The company reported $1.60 EPS for the quarter, missing the Zacks’ consensus estimate of $1.96 by ($0.36). Taro Pharmaceutical Industries had a return on equity of 11.99% and a net margin of 36.33%. The company had revenue of $158.97 million during the quarter, compared to the consensus estimate of $167.40 million. Research analysts anticipate that Taro Pharmaceutical Industries Ltd. will post 7.4 earnings per share for the current year.

The firm also recently announced a dividend, which was paid on Friday, December 28th. Shareholders of record on Tuesday, December 11th were given a $12.81 dividend. The ex-dividend date of this dividend was Monday, December 10th.

A number of equities research analysts have recently weighed in on the company. ValuEngine raised Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a report on Thursday, January 10th. HC Wainwright reissued a “buy” rating and set a $115.00 target price on shares of Taro Pharmaceutical Industries in a report on Monday, December 10th. Finally, Zacks Investment Research raised Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a report on Thursday, October 11th.

COPYRIGHT VIOLATION WARNING: This news story was reported by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/4081037/hudson-capital-management-llc-increases-holdings-in-taro-pharmaceutical-industries-ltd-taro.html.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.

Read More: How to invest in blue-chip stocks

Want to see what other hedge funds are holding TARO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taro Pharmaceutical Industries Ltd. (NYSE:TARO).

Institutional Ownership by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Commercial Metals  Stock Price Down 6.3%
Commercial Metals Stock Price Down 6.3%
Marina Biotech  Trading Down 6%
Marina Biotech Trading Down 6%
$2.66 Billion in Sales Expected for CenterPoint Energy, Inc.  This Quarter
$2.66 Billion in Sales Expected for CenterPoint Energy, Inc. This Quarter
Traid Market Cap Reaches $0.00
Traid Market Cap Reaches $0.00
Sphre AIR   Trading Down 46.1% Over Last 7 Days
Sphre AIR Trading Down 46.1% Over Last 7 Days
Analysts Expect Westport Fuel Systems Inc  to Post -$0.04 EPS
Analysts Expect Westport Fuel Systems Inc to Post -$0.04 EPS


© 2006-2019 Ticker Report